SCOPUS BIOPHARMA INC (SCPS) Stock Overview
USA - NASDAQ:SCPS - US8091711015 - Common Stock
SCPS Key Statistics, Chart & Performance
The current stock price of SCPS is 0.1682 USD. In the past month the price decreased by -30.61%. In the past year, price decreased by -91.55%.
SCPS Latest News, Press Relases and Analysis
SCPS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 69.37B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Related stock screener links
About SCPS
Company Profile
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.
Company Info
SCOPUS BIOPHARMA INC
420 Lexington Ave Rm 300
New York City NEW YORK US
Employees: 9
Phone: 12124792513.0
SCOPUS BIOPHARMA INC / SCPS FAQ
Can you describe the business of SCOPUS BIOPHARMA INC?
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.
Can you provide the latest stock price for SCOPUS BIOPHARMA INC?
The current stock price of SCPS is 0.1682 USD. The price decreased by -50.54% in the last trading session.
Does SCPS stock pay dividends?
SCPS does not pay a dividend.
What is the ChartMill technical and fundamental rating of SCPS stock?
SCPS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is SCPS stock listed?
SCPS stock is listed on the Nasdaq exchange.
Would investing in SCOPUS BIOPHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCPS.
SCPS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SCPS. When comparing the yearly performance of all stocks, SCPS is a bad performer in the overall market: 93.7% of all stocks are doing better.
SCPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SCPS. Both the profitability and financial health of SCPS have multiple concerns.
SCPS Financial Highlights
Over the last trailing twelve months SCPS reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 40.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCPS Forecast & Estimates
7 analysts have analysed SCPS and the average price target is 12.24 USD. This implies a price increase of 7177.05% is expected in the next year compared to the current price of 0.1682.